Singapore, better known to the world as the Asia-Pacific region's busiest port and a flourishing financial and banking center, will also be developed as a strategic base for manufacturing pharmaceutical and health care products for international markets, the Republic's Minister for Health and Minister for Information and Arts announced, George Yeo, while opening a new manufacturing plant for Baxter Healthcare Far East in Singapore last month.
"For the pharmaceutical and health care industry, our intent is to develop Singapore as a strategic base for the world-scale manufacture of pharmaceutical and health care products, with an emphasis on research and development and linkages to biotechnology and medical services," Mr Yeo pointed out.
Mr Yeo said that Singapore has restructured its health system to provide better and more cost-effective health care. "We are also adopting health care systems to see if they will lower cost and improve services," he added.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze